Namouni Fouad 4

What Happened
Namouni Fouad, a director of Vor Biopharma (VOR), was granted a derivative award of 56,549 shares on 2026-06-11. The award is reported at $0.00 cost (total reported value $0) and is an option-type derivative subject to a multi-month vesting schedule. This was an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
• Instrument: Derivative award (option-type) reported as code "A" — 56,549 shares at $0.00.
• Vesting: One thirty-sixth of the shares subject to the option vests on July 11, 2026 and each month thereafter (36 monthly installments), subject to continued service.
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• No sale or cashless exercise reported — this is a service-based grant, not an immediate monetization.

Context: This is a standard equity award tied to continued service and future vesting. Because it’s a derivative grant with a vesting schedule (not an open-market purchase), it does not represent an immediate buy or sell in the market; its future value will depend on Vor Biopharma’s stock performance and any exercise/settlement terms when vested.